Iribarren Cristina, Maasfeh Lujain, Öhman Lena, Simrén Magnus
Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Gut Microbiome (Camb). 2022 Aug 25;3:e7. doi: 10.1017/gmb.2022.6. eCollection 2022.
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction with a complex pathophysiology. Growing evidence suggests that alterations of the gut microenvironment, including microbiota composition and function, may be involved in symptom generation. Therefore, attempts to modulate the gut microenvironment have provided promising results as an indirect approach for IBS management. Antibiotics, probiotics, prebiotics, food and faecal microbiota transplantation are the main strategies for alleviating IBS symptom severity by modulating gut microbiota composition and function (eg. metabolism), gut barrier integrity and immune activity, although with varying efficacy. In this narrative review, we aim to provide an overview of the current approaches targeting the gut microenvironment in order to indirectly manage IBS symptoms.
肠易激综合征（IBS）是一种肠-脑相互作用紊乱的疾病，其病理生理学复杂。越来越多的证据表明，肠道微环境的改变，包括微生物群的组成和功能，可能参与症状的产生。因此，作为IBS管理的一种间接方法，调节肠道微环境的尝试已取得了有前景的结果。抗生素、益生菌、益生元、食物和粪便微生物群移植是通过调节肠道微生物群组成和功能（如代谢）、肠道屏障完整性和免疫活性来减轻IBS症状严重程度的主要策略，尽管疗效各不相同。在这篇叙述性综述中，我们旨在概述目前针对肠道微环境以间接管理IBS症状的方法。
